—

Halozyme Therapeutics Inc (HALO) — the peer cohort

As of 2026-10-13 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Halozyme Therapeutics Inc ranks 1 of 7 in its cohort on the Closelooknet composite (74/100) — the highest reading in the cohort.

NameCompositeMomentumQualityValuationSignalOff 52w high
HALO Halozyme Therapeutics Inc 74 93 94 48 ok 6.2%
ARGX.BR Argen-X 63 53 75 29 info 22.3%
ONC BeiGene, Ltd. 63 75 62 30 info 9.4%
ARGX argenx NV ADR 62 47 74 29 info 25.2%
KRYS Krystal Biotech Inc 60 61 85 17 info 16%
REGN Regeneron Pharmaceuticals Inc 60 63 70 50 watch 11.2%
UCB.BR UCB SA 60 15 69 57 warn 31.3%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-13

Quick answers

Who are Halozyme Therapeutics Inc's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Argen-X (ARGX.BR), BeiGene, Ltd. (ONC), argenx NV ADR (ARGX), Krystal Biotech Inc (KRYS), Regeneron Pharmaceuticals Inc (REGN), UCB SA (UCB.BR).

How does HALO score against its peers?

Halozyme Therapeutics Inc's composite reads 74/100, ranking 1 of 7 in its cohort as of 2026-10-13 — the highest in the cohort. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.